Mutations in the Splicing Factor SF3B1 Are Linked to Frequent Emergence of HLA-DR Monocytes in Lower-risk Myelodysplastic Neoplasms

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2024 Apr 17

PMID 38632316

Authors

Susann Winter

Marie Schneider

Uta Oelschlaegel

Giulia Maggioni

Elena Riva

Marco Gabriele Raddi

Sara Bencini

Benedetta Peruzzi

Desmond Choy

Rita Antunes Dos Reis

Esther Guse

Christopher Lischer

Julio Vera

Jessica A Timms

Nicolas Sompairac

Katja Sockel

Antonella Poloni

Antje Tunger

Matteo Giovanni Della Porta

Valeria Santini

Marc Schmitz

Uwe Platzbecker

Shahram Kordasti

Affiliations

Soon will be listed here.

Citing Articles

Alternative Splicing: A Potential Therapeutic Target in Hematological Malignancies.

Temaj G, Chichiarelli S, Saha S, Telkoparan-Akillilar P, Nuhii N, Hadziselimovic R Hematol Rep. 2024; 16(4):682-697.

PMID: 39584923 PMC: 11587037. DOI: 10.3390/hematolrep16040066.

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.

Rodriguez-Sevilla J, Adema V, Chien K, Loghavi S, Ma F, Yang H Nat Commun. 2024; 15(1):9840.

PMID: 39537648 PMC: 11561093. DOI: 10.1038/s41467-024-54290-2.

References

Huber S, Haferlach T, Meggendorfer M, Hutter S, Hoermann G, Baer C . SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia. 2022; 36(12):2894-2902. PMC: 9712089. DOI: 10.1038/s41375-022-01728-5. View

Lieu Y, Liu Z, Ali A, Wei X, Penson A, Zhang J . SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2021; 119(1). PMC: 8740767. DOI: 10.1073/pnas.2111703119. View

Clough C, Pangallo J, Sarchi M, Ilagan J, North K, Bergantinos R . Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood. 2021; 139(13):2038-2049. PMC: 8972092. DOI: 10.1182/blood.2021012652. View

Mortera-Blanco T, Dimitriou M, Woll P, Karimi M, Elvarsdottir E, Conte S . -initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. Blood. 2017; 130(7):881-890. PMC: 5572789. DOI: 10.1182/blood-2017-03-776070. View

Platzbecker U, Germing U, Gotze K, Kiewe P, Mayer K, Chromik J . Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017; 18(10):1338-1347. DOI: 10.1016/S1470-2045(17)30615-0. View

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres M, Brunner A . The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018; 2(14):1765-1772. PMC: 6058241. DOI: 10.1182/bloodadvances.2018019414. View

Zhang Q, Haider M, Al Ali N, Lancet J, Epling-Burnette P, List A . SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020; 20(6):400-406.e2. PMC: 7771378. DOI: 10.1016/j.clml.2019.12.023. View

Duetz C, Westers T, In t Hout F, Cremers E, Alhan C, Venniker-Punt B . Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype. Br J Haematol. 2021; 193(4):798-803. PMC: 8252736. DOI: 10.1111/bjh.17414. View

Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J . SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020; 136(2):157-170. PMC: 7362582. DOI: 10.1182/blood.2020004850. View

10.

Schneider M, Rolfs C, Trumpp M, Winter S, Fischer L, Richter M . Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia. 2023; 37(8):1709-1718. PMC: 10400420. DOI: 10.1038/s41375-023-01949-2. View

11.

van Leeuwen-Kerkhoff N, Westers T, Poddighe P, de Gruijl T, Kordasti S, van de Loosdrecht A . Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation. Haematologica. 2019; 105(4):961-971. PMC: 7109736. DOI: 10.3324/haematol.2019.219303. View

12.

Mengos A, Gastineau D, Gustafson M . The CD14HLA-DR Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. Front Immunol. 2019; 10:1147. PMC: 6540944. DOI: 10.3389/fimmu.2019.01147. View

13.

Todisco G, Moura P, Hellstrom-Lindberg E . Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?. Semin Hematol. 2022; 59(3):150-155. DOI: 10.1053/j.seminhematol.2022.08.002. View

14.

Chun-Wei Lee S, North K, Kim E, Jang E, Obeng E, Lu S . Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell. 2018; 34(2):225-241.e8. PMC: 6373472. DOI: 10.1016/j.ccell.2018.07.003. View

15.

Choudhary G, Pellagatti A, Agianian B, Smith M, Bhagat T, Gordon-Mitchell S . Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022; 11. PMC: 9427103. DOI: 10.7554/eLife.78136. View